Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 2, 2025

Supplementary Figure 6 from Sustained Macrophage Reprogramming Is Required for CD8+ T cell–Dependent Long-Term Tumor Eradication

View Full Paper
Ask AI
Bookmark
Share

Authors

CJCarolina JardimMBMarta BicaMRMariana Reis-Sobreiro

Discussion

Loading...

Member takes

Overview

Findings show macrophage reprogramming enhances T cell activity in tumors, suggesting a pathway for effective cancer treatment.

Key Points

  • Core finding shows sustained macrophage reprogramming is crucial for effective tumor eradication.
  • Data indicates that enhanced CD8+ T cell responses are linked to macrophage changes in the tumor environment.
  • Research involved evaluating macrophage behavior and its impact on T cell function in cancer models.
  • Results imply that targeting macrophage reprogramming may improve long-term tumor control in cancer therapies.

Cite This Study

Jardim et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d016chttps://doi.org/10.1158/2326-6066.29760902
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from Sustained Macrophage Reprogramming Is Required for CD8<sup>+</sup> T cell–Dependent Long-Term Tumor Eradication2025
  2. 2Supplementary Figure 15 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma2025
  3. 3Supplementary Figure 14 from SPP1<sup>+</sup> Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8<sup>+</sup> T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma2025
  4. 4Supplementary Figure 6 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool2024
  5. 5Supplementary Figure 6 from CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool2024